Patient Care
Academic expertise in a private clinical setting
We are pioneers, innovators, researchers, and educators. Yale School of Medicine Department of Obstetrics, Gynecology and Reproductive Sciences has been at the forefront of major breakthroughs and meaningful refinements on many aspects of women’s health. Simply put, we are here to care for you with the very latest knowledge and techniques when you need it most and have been ranked #4 nationally by the U.S. News & World Report.
Programs & Specialties
Fact Sheets
Pain Management for C-Sections
Giving birth by Cesarean section (C-section) is safer than ever. Today's anesthesiology and pain management treatments ease pain for mothers.
Read moreAbnormal Uterine Bleeding
Abnormal uterine bleeding—or menstrual bleeding that is unpredictable in timing, amount or duration—is a common problem among women. Learn about symptoms and treatment.
Read morePelvic Organ Prolapse
Pelvic organ prolapse occurs when the pelvic floor weakens, leading the organs to descend or herniate into the vagina.
Read moreAnesthesia for Fibroid Surgery
Women with uterine fibroids who opt to have them surgically removed will usually be given general anesthesia before their procedure.
Read moreNews from Yale Medicine
In the News
Clinical Trials
A Historical Cohort, Multicenter Study to Characterize the Management, Clinical Course, and Outcomes of Pregnancies in Women Who Have Experienced a Pregnancy With Early Onset Severe HDFN
AgeANY
GenderANY
Date21 February
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
AgeANY
GenderANY
Date24 April
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
AgeANY
GenderANY
Date20 December
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome
AgeANY
GenderANY
Date20 December